PDCD1 and neoplasm: In other solid tumors, immune checkpoint blockade targeting inhibitory receptors expressed on T cells such as cytotoxic T lymphocyte–associated protein 4 (CTLA-4) or programmed cell death 1 (PD-1) elicits clinical improvement and tumor regression (48–50).